Travere Therapeutics (TVTX) Accounts Payables (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Accounts Payables came in at $12.9 million in Q1 2026, down 16.01% YoY from $15.4 million in Q1 2025, and down 47.94% on a QoQ basis from $24.8 million in Q4 2025.
Travere Therapeutics (TVTX) Accounts Payables (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Accounts Payables data on file, last reported at $12.9 million in Q1 2026.
- Quarterly Accounts Payables fell 16.01% year-over-year to $12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.9 million (down 16.01% YoY) and the FY2025 annual result came in at $24.8 million, up 5.38% from the prior year.
- Accounts Payables fell to $12.9 million in Q1 2026, from $24.8 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $41.7 million in Q4 2023 to a low of $11.8 million in Q2 2022.
- A 5-year average of $20.3 million and a median of $18.4 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 141.04% — and 2024, when it sank 43.53%.
- Tracing TVTX's Accounts Payables over 5 years: stood at $17.3 million in 2022, then jumped by 141.04% to $41.7 million in 2023, then slumped by 43.53% to $23.5 million in 2024, then increased by 5.38% to $24.8 million in 2025, then tumbled by 47.94% to $12.9 million in 2026.
- The last three Accounts Payables figures came in at $12.9 million (Q1 2026), $24.8 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 7.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.50 Mn |
| Mar 31, 2026 | 12.91 Mn |
| Dec 31, 2025 | 24.80 Mn |
| Sep 30, 2025 | 18.23 Mn |
| Jun 30, 2025 | 19.13 Mn |
| Mar 31, 2025 | 15.37 Mn |
| Dec 31, 2024 | 23.53 Mn |
| Sep 30, 2024 | 23.20 Mn |
| Jun 30, 2024 | 25.84 Mn |
| Mar 31, 2024 | 16.73 Mn |
| Dec 31, 2023 | 41.68 Mn |
| Sep 30, 2023 | 24.74 Mn |
| Jun 30, 2023 | 19.92 Mn |
| Mar 31, 2023 | 16.73 Mn |
| Dec 31, 2022 | 17.29 Mn |
| Sep 30, 2022 | 14.01 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 18.43 Mn |
| Dec 31, 2021 | 15.14 Mn |
| Sep 30, 2021 | 5.83 Mn |